Heart Failure Management with Beta-Blockers

Introduction to Beta-Blockers

Bisoprolol and metoprolol are beta-blockers that effectively reduce mortality in heart failure patients with reduced ejection fraction (HFrEF) when used at appropriate doses, according to the American Heart Association 1
The European Society of Cardiology recommends the use of beta-blockers, such as bisoprolol and metoprolol, in the management of heart failure 2

Bisoprolol has a higher beta-1 selectivity, which may provide clinical advantages in patients with respiratory conditions, as stated by the American College of Cardiology 1
Metoprolol has a moderate beta-1 selectivity, but is still preferable to non-selective beta-blockers in patients with respiratory issues, according to the European Respiratory Society 3
Bisoprolol has a longer half-life, allowing for once-daily dosing, with a target dose of 10 mg once daily, as recommended by the European Heart Journal 2
Metoprolol is available in immediate-release (tartrate) and extended-release (succinate) formulations, with target doses of 50 mg twice daily for tartrate and 200 mg once daily for succinate, as stated by the European Heart Journal 2

Both bisoprolol and metoprolol reduce mortality in heart failure with reduced ejection fraction (HFrEF) when used at appropriate doses, with a strength of evidence rated as high by the American College of Cardiology 1
The CIBIS-II trial showed a 34% reduction in all-cause mortality with bisoprolol, with a number needed to treat (NNT) of 23 patients to prevent one death, as reported by the Journal of the American Medical Association 4
The MERIT-HF trial showed a 34% reduction in all-cause mortality with metoprolol succinate, with a NNT of 27 patients to prevent one death, as reported by the Journal of the American Medical Association 4

Women may experience greater adverse effects with metoprolol due to higher drug exposure, and may benefit from lower-than-standard doses to reduce adverse reaction risk, as stated by the American College of Clinical Pharmacology 3
Bisoprolol showed a significantly greater reduction in mortality in women compared to men in the CIBIS II trial, with a strength of evidence rated as moderate by the American College of Cardiology 3
Elderly patients can use both medications, but careful dose titration is essential, as recommended by the American Geriatrics Society 2

Bisoprolol can be started at 1.25 mg and titrated to a target dose of 10 mg once daily, as recommended by the European Heart Journal 2
Metoprolol succinate can be started at 12.5-25 mg and titrated to a target dose of 200 mg once daily, as recommended by the European Heart Journal 2
Metoprolol tartrate can be started at 5 mg and titrated to a target dose of 50 mg twice daily, as recommended by the European Heart Journal 2

Using inadequate doses: titrate to target doses shown to be effective in clinical trials, as recommended by the American Heart Association 1
Confusing metoprolol formulations: succinate (extended-release) and tartrate (immediate-release) are not interchangeable, as stated by the European Heart Journal 2
Overlooking sex-related differences: women may need lower doses of metoprolol, as recommended by the American College of Clinical Pharmacology 3
Abrupt discontinuation: always taper beta-blockers to avoid rebound effects, as recommended by the American College of Cardiology 1